4.5 Review

Evolving role of MeCP2 in Rett syndrome and autism

期刊

EPIGENOMICS
卷 1, 期 1, 页码 119-130

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/EPI.09.13

关键词

autism; chromatin; epigenetic; imprinting; MeCP2; methylation; Rett syndrome; X chromosome inactivation

资金

  1. NICHD NIH HHS [R01 HD041462-07, R01 HD048799, R01 HD048799-05, R01 HD041462] Funding Source: Medline
  2. NIEHS NIH HHS [R01 ES015171, R01 ES015171-03] Funding Source: Medline
  3. EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041462, R01HD048799] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015171] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Rett syndrome is an X-linked autism-spectrum disorder caused by mutations in MECP2, encoding methyl CpG-binding protein 2. Since the discovery of MECP2 mutations as the genetic cause of Rett syndrome, the understanding of MeCP2 function has evolved. Although MeCP2 was predicted to be a global transcriptional repressor of methylated promoters, large-scale combined epigenomic approaches of MeCP2 binding, methylation and gene expression have demonstrated that MeCP2 binds preferentially to intergenic and intronic regions, and sparsely methylated promoters of active genes. This review compares the evolution of thought within two 'classic' epigenetic mechanisms of parental imprinting and X chromosome inactivation to that of the MeCP2 field, and considers the future relevance of integrated epigenomic databases to understanding autism and Rett syndrome.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据